Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-10-22

Clinical Trial Update: Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of a testosterone eye drop for Meibomian Gland Dysfunction has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • testosterone eye drop (testosterone)

Snippet

Sponsor: ORA, Inc. | Conditions: Meibomian Gland Dysfunction | Phase 2 | Status: COMPLETED | Results posted: 2020-10-22